PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 186 filers reported holding PDL BIOPHARMA INC in Q3 2017. The put-call ratio across all filers is 1.44 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $14,879,000 | -4.5% | 4,723,376 | -11.7% | 0.51% | +8.4% |
Q2 2020 | $15,572,000 | -3.7% | 5,351,132 | -6.7% | 0.47% | -16.3% |
Q1 2020 | $16,169,000 | -14.3% | 5,733,572 | -1.3% | 0.57% | +26.3% |
Q4 2019 | $18,857,000 | +59.7% | 5,811,080 | +6.3% | 0.45% | +46.9% |
Q3 2019 | $11,805,000 | -9.9% | 5,465,156 | +31.0% | 0.30% | +4.5% |
Q2 2019 | $13,100,000 | -19.0% | 4,171,971 | -4.0% | 0.29% | -22.3% |
Q1 2019 | $16,164,000 | +24.9% | 4,345,083 | -2.6% | 0.38% | +13.9% |
Q4 2018 | $12,943,000 | +25.0% | 4,463,103 | +13.4% | 0.33% | +41.0% |
Q3 2018 | $10,354,000 | +1522.9% | 3,936,719 | +1343.0% | 0.23% | +1571.4% |
Q2 2018 | $638,000 | -73.5% | 272,811 | -66.8% | 0.01% | -72.5% |
Q1 2018 | $2,412,000 | -20.0% | 820,741 | -25.4% | 0.05% | -16.4% |
Q4 2017 | $3,016,000 | -20.0% | 1,100,518 | -1.1% | 0.06% | -20.8% |
Q3 2017 | $3,772,000 | +31.0% | 1,112,679 | +0.5% | 0.08% | +67.4% |
Q2 2017 | $2,879,000 | +2064.7% | 1,107,310 | +1790.3% | 0.05% | +2200.0% |
Q1 2017 | $133,000 | – | 58,578 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |